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Objective: The aim of this study was to determine
whether a 3-year treatment with strontium ranelate could
delay the progression of spinal osteoarthritis (OA).
Methods: This study was a post-hoc analysis of pooled
data from the Spinal Osteoporosis Therapeutic
Intervention (SOTI) and TReatment Of Peripheral
OSteoporosis (TROPOS) trials performed on 1105 women
with osteoporosis and concomitant radiological spinal OA
at baseline, and for whom lumbar x-rays were available at
baseline and over the 3-year treatment period. The
presence and severity of osteophytes, disc space
narrowing and sclerosis in the lumbar intervertebral
spaces was graded according to a validated method, and
an overall OA score was calculated for each intervertebral
space. Back pain (measured on a five-point Likert scale
only in SOTI) and health-related quality of life (SF-36
questionnaire) were assessed at baseline and after
3 years. Patients who suffered an incident or progressive
vertebral fracture during the study were excluded from
the analysis.
Results: The proportion of patients with worsening
overall spinal OA score was reduced by 42% in the
strontium ranelate group, compared with placebo (RR,
0.58; 95% CI, 0.42 to 0.79; p = 0.0005). Significantly
more patients in the strontium ranelate group experienced
an improvement in back pain after 3 years, compared
with placebo (p = 0.03), while no significant difference
was observed in terms of health-related quality of life
between these patient groups.
Conclusions: The results of this post-hoc analysis
suggest that strontium ranelate could reduce the
progression of the radiographic features of spinal OA and
back pain in women with osteoporosis and prevalent
spinal OA.
Osteoarthritis (OA) is a major cause of disability
and is one of the most frequent musculoskeletal
disorders.1 For decades, the traditional pharmaco-
logical management of OA has been mainly
symptomatic, without the support of any well-
documented findings on the influence of treatment
on disease duration and progression. Drugs with a
favourable action on joint structure, which are
therefore able to delay the progression of the
disease, are termed structure-modifying drugs.2 3
During the last few years, several randomised
controlled trials have been performed to assess the
structure-modifying effect of various compounds,
such as diacerein,4 glucosamine sulphate,5 6 chon-
droitin sulphate,7 8 and doxycycline.9 However, all
these trials specifically addressed lower limb OA
(ie, OA of the knee and/or hip), whereas very few
data are currently available concerning spinal OA.10
Moreover, the pathophysiology of hip or knee OA
differs from that of spinal OA.11
Lumbar disc degeneration is characterised by the
presence of osteophytes, endplate sclerosis and disc
space narrowing. There is no consensus as to
whether this is a variant of general OA or a
separate phenomenon, but lumbar spine disc
degeneration is often referred to as spinal OA.12
As the severity of radiographic features of spinal
OA correlates with increased back pain and
decreased health-related quality of life,13 14 any
intervention able to delay the progression of spinal
OA would be of great interest. Moreover, progres-
sion of OA in the spine correlates significantly with
progression at other clinical sites such as hand and
knee.15
Strontium ranelate is a new drug indicated for
the treatment of postmenopausal osteoporosis,
which has been proven to be effective in the
reduction of vertebral and hip fractures.16 17
Previous studies have provided the preclinical basis
for the in vivo testing of strontium ranelate in OA.
In human normal and OA chondrocytes that are
treated with or without interleukin 1b (IL-1b),
strontium ranelate has been shown to stimulate
the synthesis of type II collagen and proteogly-
can.18 Moreover, 10–3 M strontium ranelate
increased the stimulatory effect of insulin-like
growth factor (IGF) on proteoglycan synthesis,
but did not reverse the inhibitory effect of IL-1b.18
In a 3-year post-hoc analysis of the pool of Spinal
Osteoporosis Therapeutic Intervention (SOTI) and
TReatment Of Peripheral OSteoporosis (TROPOS)
studies, strontium ranelate was also shown to
significantly decrease, at all time points, the levels
of urinary C-terminal telopeptides of type II
collagen (u-CTX-II), a cartilage degradation bio-
marker with high tissue specificity, compared with
placebo.19
The aim of the present study was to assess the
efficacy of a 3-year treatment with strontium
ranelate in delaying the clinical and structural
progression of spinal OA.
METHODS
The present study is a post-hoc analysis of the
SOTI and TROPOS trials.16 17 The design and
methodology of these two studies have been
described fully elsewhere. Briefly, ambulatory
postmenopausal women were recruited in 11
European countries and in Australia into two
prospective, randomised, double-blind, placebo
controlled trials SOTI and TROPOS. Women were
eligible for the SOTI trial if they were at least
50 years old, had been postmenopausal for at least
Extended report
Ann Rheum Dis 2008;67:335–339. doi:10.1136/ard.2007.075572 335
 on 8 July 2009 ard.bmj.comDownloaded from 
5 years, had at least one prevalent vertebral fracture confirmed
by spinal radiography and had a lumbar spine bone mineral
density of 0.840 g/cm2 or less. In the TROPOS trial, the
eligibility criteria included a femoral neck bone mineral density
of 0.600 g/cm2 (corresponding to a T-score ,22.5); age 74 years
or older; or age between 70 and 74 years with at least one
additional risk factor for fracture. In both studies, patients
received either 2 g/day strontium ranelate or placebo, for
3 years. Calcium and vitamin D supplementation was pre-
scribed throughout the course of both trials, the dosage having
been determined during a run-in period. All participants gave
written informed consent before enrolment and both studies
were approved by the relevant institutional review boards.
Lumbar spine vertebral radiographs were evaluated at base-
line (month 0 [M0]) and after 3 years (month 36 [M36]) (or
M24 in 579 patients for whom M36 radiographs were
unavailable or not assessable). In SOTI and TROPOS, only
lateral spine radiographs were available. A total of 4224 patients
had both a baseline and post-baseline x-ray (fig 1). Four
intervertebral spaces (L1–L2, L2–L3, L3–L4 and L4–L5) were
examined for the presence and severity of anterior osteophytes
(score 0–3), posterior osteophytes (score 0–3), joint space
narrowing (score 0–3) and sclerosis (score 0–1), and graded
using an atlas according to the method of Lane et al.20 This
enabled calculation of an overall OA score for each interverteb-
ral space (graded from 0 to 2) as suggested in the original
publication (table 1).20
Of the 4224 patients, 2395 have all lumbar intervertebral
spaces assessable (fig 1). All radiographs were read by the same
person, who was blinded both to the treatment (strontium
ranelate or placebo) and to the time sequence of radiograph
acquisition (M0 or M36). The reproducibility (test–retest of 40
radiographs over a 2-week interval) of these qualitative
assessments was high, with a Kappa score between 0.85 and
0.92. The reproducibility of sclerosis assessment could not be
evaluated because the number of patients with sclerosis was too
small.
All patients were also asked to fill in the 36-item Short-Form
health survey (SF-36). The SF-36 consists of 36 multiple-choice
items comprising eight health domains that describe the overall
health-related quality of life as reported by the subject.21 Four
dimensions refer to physical health and four others to mental
health. All subscales were scored using the Likert scale, with
lower scores indicating a perception of poorer health, loss of
function and presence of pain. The SF-36 has consistently
shown high levels of reliability (test–retest and internal
consistency reliability) and validity (content, concurrent,
criterion-related, construct and predictive validity).21
As initially planned in the SOTI trial, patients were also asked
to reply, at baseline and every 6 months, to one question related
to back pain, using a five-point Likert scale: ‘‘During the past
4 weeks, have you had pain in the middle or upper part of your
back?’’. The possibility of response was ‘‘not at all, no pain’’, ‘‘a
little’’, ‘‘moderately’’, ‘‘quite a bit’’ and ‘‘a great deal’’. This
question was part of the Qualiost questionnaire.22
Statistical analysis
Our post-hoc analysis was carried out in patients with and
without prevalent vertebral fractures, who had prevalent spinal
radiographic OA (overall OA score >1 for each intervertebral
space). However, as initially planned, patients who had suffered
a new vertebral fracture or the worsening of a prevalent fracture
during the trial were excluded (in order to avoid interference
with the evaluation of spinal interspace and osteophyte
formation). The primary efficacy outcome was defined as the
proportion of patients in the strontium ranelate and placebo
groups in whom the overall OA score increased by at least one
grade of severity (in one or more intervtertebral spaces) during
the 3-year follow-up period. The statistical difference between
the two groups was assessed by the x2 test. The secondary end
point in our study was the difference in the proportion of
patients, in the strontium ranelate and placebo groups, with a
progression in the score of any single one of the radiographic
features (ie, osteophytes, narrowing of disc space, or sclerosis),
during the 3-year follow-up. Secondary analyses also included
the analysis in the whole study population (with or without
prevalent spine OA) but also in patients with at least one
intervertebral space with spinal OA. Changes in health-related
quality of life scores after 3 years in both groups were assessed
using the Mann–Whitney U test. The proportion of patients
having experienced an improvement in back pain of at least one
point on the Likert scale was calculated in the strontium
ranelate and placebo groups, and the statistical difference
between the two groups was assessed by the x2 test.
Assessment of health-related quality of life was only performed
in patients without new non-vertebral fractures (n = 880) in
order to avoid any influence of such fractures on the overall
Figure 1 Study flowchart. OA, osteoarthritis; SOTI, Spinal Osteoporosis
Therapeutic Intervention; TROPOS; TReatment Of Peripheral
OSteoporosis.
Table 1 Individual lumbar disc degeneration features leading to the
calculation of an overall osteoarthritis (OA) score
Lumbar disc degeneration Overall OA score
Normal joint (0 for osteophytes, disc space
narrowing and sclerosis)
0
Mild (1) narrowing and/or mild (1) osteophytes 1
Moderate–severe (2–3) narrowing and/or
moderate–severe (2–3) osteophytes and/or
presence (1) of sclerosis
2
The numbers in parentheses correspond to grades of individual radiographic features.
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assessment of quality of life. Only the subgroup of patients
form the SOTI trial replied to the question about back pain
(n = 399). At least, we have looked at the proportion of
patients, in each group, with new concomitant treatment
taken for their OA.
RESULTS
Baseline characteristics of the study population are summarised
in table 2. There were no statistical differences in the baseline
characteristics between the strontium ranelate group and the
placebo group.
At the end of the 3-year follow-up, 13.4% of patients
experienced an increase in overall spinal OA score involving at
least one intervertebral space. The proportion of patients with
an overall OA score progression was 3.9%, 3.7%, 4.8% and 3.6%
for the L1–L2, L2–L3, L3–L4 and L4–L5 intervertebral spaces,
respectively.
After 3 years of study, only 9.9% in the strontium ranelate
group experienced an increase in the overall OA score, versus
17.1% in the placebo group. The proportion of patients with an
increase in the overall OA score was reduced by 42% in the
strontium ranelate group, compared with placebo (RR, 0.58;
95% CI, 0.42 to 0.79; p = 0.0005) (fig 2).
After 3 years of treatment the number of patients in whom
the disc space narrowing score worsened was significantly
reduced by 33% in the strontium ranelate group, compared with
placebo (RR 0.67; 95% CI, 0.47 to 0.97; p = 0.03). There was
also an absolute reduction in the proportion of patients with an
increased severity of the osteophyte score in the strontium
ranelate group, compared with placebo, but this finding did not
reach statistical significance (table 3).
When our analysis is performed in the whole study
population (ie, with or without prevalent spine OA;
n = 2395), 29.5% in the strontium ranelate group experienced
an increase in the overall spinal OA score after 3 years, versus
31.8% in the placebo group. As a matter of fact, strontium
ranelate was not able to significantly reduce, compared with
placebo, the proportion of patients with an increase in the
overall OA score (p = 0.23), disc space narrowing (p = 0.93) or
anterior osteophytes (p = 0.43) or posterior osteophytes
(p = 0.42). In patients with at least one intervertebral space
with OA, the proportion of patients with a progressive OA score
was reduced by 9%, compared with placebo, but these results
did not reach statistical significance (p = 0.14). The same trends
have been shown for disc space narrowing, and anterior and
posterior osteophytes (p = 0.78, 0.23 and 0.39, respectively).
After 3 years of treatment, more patients from the strontium
ranelate group (84 of 201; 41.8%) experienced an improvement
in back pain (decrease by at least one point on the Likert scale)
compared with placebo (62 of 198; 31.3%; p = 0.03). Figure 3
show the change in the Likert scale in the placebo and the
strontium ranelate group during the 3 years of follow-up. In the
whole study population, no significant improvements were
observed in any of the items of the SF-36 in the strontium
ranelate group, compared with placebo (p-value between 0.18
and 0.93). In particular, there were no changes in the Physical
and Mental component scores (p = 0.74 and p = 0.73, respec-
tively).
During the 3 years of follow-up, 10.5% of patients from the
placebo group took a treatment related to their OA, compared






(n = 539) p
Age: years 72.9 (6.5) 73.1 (7.4) 0.55
BMI: kg/m2 25.9 (3.9) 25.8 (4.0) 0.91
Lumbar BMD: g/cm2 0.772 (0.145) 0.778 (0.143) 0.46
Hip BMD: g/cm2 0.669 (0.101) 0.668 (0.097) 0.82
Number of prevalent vertebral
fractures
1.69 (2.23) 1.56 (2.1) 0.24
BMD, bone mineral density.
Figure 2 The percentage of patients with an increase in the overall
score after 3 years’ follow-up among the whole study population.
Table 3 Percentage of patients with worsening of osteoarthritis (OA)
grading (n = 1105)
Strontium
ranelate
n = 566 (%)
Placebo
n = 539 (%) p RR (95% CI)












1.4 2.6 0.16 0.55
(0.23 to 1.29)
Sclerosis 0 0.2 NA NA
Figure 3 Evolution of back pain on the five-point Likert scale in the
strontium ranelate and placebo groups during 3 years of follow-up.
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with 8.3% of the patients from the strontium ranelate group
(RR 0.78; 95% CI, 0.55 to 1.12; p = 0.18).
DISCUSSION
This post-hoc analysis suggests that strontium ranelate reduces
radiographic spine OA progression in women with osteoporosis
and prevalent spinal OA, with or without prevalent vertebral
fractures. Concomitantly, a reduction in back pain was
observed during the course of the 3-year treatment with
strontium ranelate. These findings suggest that strontium
ranelate may have symptom- and structure-modifying effects
in women with osteoporosis and OA. New, prospective
randomised controlled trials in patients with knee OA are
currently ongoing to further confirm the potential structure-
modifying effect of strontium ranelate.
Various methods have been proposed for assessing the
severity of lumbar disc degeneration. Kellgren and Lawrence
developed a grading scale.23 Lane et al sought to improve the
moderate test–retest agreement and interrater agreement by
defining radiographic indices of lumbar disc degeneration to
evaluate the individual radiographic features of disc degenera-
tion (ie, anterior osteophytes, posterior osteophytes, joint space
narrowing and sclerosis). They were thus able to assign a
summary grade derived directly from the evaluation of the
selected radiographic features.20 The authors of the original
study that validated this method also evaluated the two most
frequently affected dorsal intervertebral spaces.20 In the present
study, we used this method to assess lumbar spine OA. It
should also be pointed out that the method of Lane et al and the
views available did not allow assessment of intervertebral
posterior articular or facet joints.20
Whether the occurrence of osteophytes and joint space
narrowing are separate phenomena or not in the context of
lumbar spine disc degeneration, remains unclear.12 In this study,
we report a reduction in the progression of joint space
narrowing with strontium ranelate, compared with placebo.
Data are scarce with regard to therapies modifying the course of
OA,4–10 especially in the spine,10 To the best of our knowledge,
only one post-hoc analysis has shown that alendronate reduced
spinal osteophyte formation in women with osteoporosis
(n = 200), but no data on disc space narrowing were provided.10
Strontium ranelate is a drug registered for the treatment of
osteoporosis. Other osteoporotic drugs have been tested for
their structure-modifying properties in OA, but with conflicting
results.10 24 25 Alendronate has been reported to reduce spinal
osteophyte formation,10 but two prospective placebo controlled
studies found that risedronate failed to significantly reduce the
radiographic progression of knee OA (ie, joint space narrow-
ing).24 25
We hypothesise that the effect on joint space narrowing and
osteophytes may be due to a direct effect of strontium ranelate
on cartilage and bone resulting in endochondral ossification.
Although the effects of strontium ranelate on bone have been
well described,26 few data are currently available on its effect on
cartilage.18 19 In normal chondrocytes and chondrocytes with
OA, cultured for 24–72 hours in the presence or absence of
strontium ranelate at concentrations ranging from 10–4 to
10–3 M, 1 mM strontium ranelate stimulated human cartilage
matrix formation (type II collagen and proteoglycan synthesis),
via a direct ionic effect, without stimulating chondroresorption
processes.18 Measurement of u-CTX-II was carried out in a
subset of 2617 postmenopausal women with osteoporosis from
the phase III clinical trial TROPOS.19 A total of 1310 patients
was assigned to active treatment for 3 years with strontium
ranelate 2 g/day, while 1307 patients received placebo. During
the 3-year trial period, at all time points, there was a significant
decrease in u-CTX-II of about 15–20% in the strontium
ranelate-treated group, compared with placebo (p,0.001).19
It should be pointed out that strontium ranelate seems to be
less effective in patients without prevalent OA at each
intervertebral space suggesting that this drug could not be
considered as a preventive treatment of incident spinal OA.
Our study did not show any significant improvement in
health-related quality of life in patients taking strontium
ranelate compared with placebo. However, it should be
emphasised that the SF-36 questionnaire used in this study
was a general questionnaire not OA-specific. The SOTI and
TROPOS trials were initially designed to assess the effect of
strontium ranelate on fracture incidence. As a consequence, no
specific OA questionnaires were used. The only question
relating, at least in part, to OA symptoms was the ‘‘back pain’’
question. However, this question was not specifically restricted
to the lumbar spine. Moreover, this question was only used in
the SOTI trial and not addressed to the whole study population.
Nevertheless, more patients in the strontium ranelate group
experienced an improvement in back pain than in the placebo
group even after excluding patients with incident fractures.
The study we report here has strengths as well as limitations.
It was a post-hoc analysis of two prospective placebo controlled
3-year trials, in which the patients included were rigorously
followed and radiograph acquisition was fully standardised.16 17
The radiographs were read by a single trained person blinded to
the treatment group and the time sequence of radiograph
acquisition. However, no data on peripheral OA were available,
nor did we assess thoracic spine OA. Moreover, the method of
assessment of lumbar spine degeneration did not allow
assessment of intervertebral posterior articular joints and lateral
osteophytes or direct changes in the disc, which may also
contribute to symptoms. At least, our results could not be
extrapolated to all patients with lumbar OA as our study
population consists of postmenopausal women with osteoporo-
sis.
In conclusion, our findings suggest that strontium ranelate
reduces the progression of radiographic spinal OA and back pain
in women with osteoporosis and spinal OA. This study has
implications not only in the potential treatment of chronic back
pain, but also for progression of OA at other sites.
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The terms and conditions of the Grant are as follows:
c At least one of the applicants must be a member of COPE.
c Calls for applications will be made twice a year with closing dates of 1 December and 1 June. An
electronic version of the application form must be sent to the Administrator no later than 12 pm
(noon GMT) on the closing date for consideration by COPE Council.
c The application must contain a lay summary of the project, a definition of the question to be posed,
sufficient methodological detail to allow assessment of the viability of the project, a clear timeline
and a definition of the likely deliverables. A full justification for the sum requested must accompany
the application.
c A report on the progress of the research should be presented within one year of the award and at
the end of the project. The grant must be used within two years from the date of award, and balance
sheets must be forwarded annually. These should be sent to the Administrator. Any remaining funds
after two years must be returned.
c It is anticipated that the work stemming from the project will be presented at one of COPE’s annual
seminar meetings within 2–3 years of the award. Such data may also be published in peer-reviewed
journals. Any publications or related presentations at meetings by the recipient emanating in part or
whole from COPE’s support should be duly acknowledged and copies sent to the Administrator.
Applications are reviewed by a COPE sub-committee. Applicants will be advised of a decision as soon
as practicable after the deadline date.
An application form can be obtained by contacting Linda Gough, COPE administrator, at LGough@
bmj.com or 020 7383 6602. For more information on COPE, see http://www.publicationethics.org.uk/
The closing date for receipt of applications is 1 December 2007 or 1 June 2008.
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